» Articles » PMID: 27037951

Body Mass Index and Risk of Colorectal Cancer According to Tumor Lymphocytic Infiltrate

Overview
Journal Int J Cancer
Specialty Oncology
Date 2016 Apr 3
PMID 27037951
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Higher body mass index (BMI), higher body adiposity and obesity have been associated with increased risk of colorectal cancer. Evidence suggests that excess energy balance may influence systemic immune and inflammatory status. Thus, we hypothesized that the positive association between BMI and colorectal cancer risk might differ according to colorectal carcinoma subtypes according to levels of histopathological lymphocytic reaction to tumor. We collected biennial questionnaire data on weight and baseline height information in two prospective cohort studies, the Nurses' Health Study (1980-2010) and the Health Professionals Follow-up Study (1986-2010). Utilizing duplication-method Cox proportional hazards regression models, we prospectively assessed the association between BMI and risk of colorectal cancer subtypes according to the degree of Crohn's-like lymphoid reaction, peritumoral lymphocytic reaction, intratumoral periglandular reaction, tumor-infiltrating lymphocytes, the overall lymphocytic reaction score, or T-cell [CD3(+) , CD8(+) , CD45RO (PTPRC)(+) or FOXP3(+) ] density in tumor tissue. Statistical significance level was adjusted for multiple hypotheses testing by Bonferroni correction. During follow up of 1,708,029 men and women (over 3,346,752 person-years), we documented 1,436 incident rectal and colon cancer cases with available formalin-fixed paraffin-embedded tumor tissue materials and pathological immunity data. BMI was significantly associated with higher risk of overall colorectal cancer (Ptrend  < 0.001); however, the association of BMI with colorectal carcinoma risk did not significantly differ by the level of lymphocytic reaction or T-cell infiltration in tumor tissue status (Pheterogeneity  > 0.10). BMI may be associated with risk of colorectal cancer regardless of levels of lymphocytic response to tumor.

Citing Articles

Heterogeneity of the tumor immune microenvironment and clinical interventions.

Jin Z, Zhou Q, Cheng J, Jia Q, Zhu B Front Med. 2023; 17(4):617-648.

PMID: 37728825 DOI: 10.1007/s11684-023-1015-9.


Body mass index and molecular subtypes of colorectal cancer.

Murphy N, Newton C, Song M, Papadimitriou N, Hoffmeister M, Phipps A J Natl Cancer Inst. 2022; 115(2):165-173.

PMID: 36445035 PMC: 9905970. DOI: 10.1093/jnci/djac215.


Weight Loss and/or Sulindac Mitigate Obesity-associated Transcriptome, Microbiome, and Protumor Effects in a Murine Model of Colon Cancer.

Bowers L, Glenny E, Punjala A, Lanman N, Goldbaum A, Himbert C Cancer Prev Res (Phila). 2022; 15(8):481-495.

PMID: 35653548 PMC: 9357192. DOI: 10.1158/1940-6207.CAPR-21-0531.


Energy balance-related factors and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status.

Jenniskens J, Offermans K, Simons C, Samarska I, Fazzi G, van der Meer J J Cancer Res Clin Oncol. 2022; 148(10):2723-2742.

PMID: 35546360 PMC: 9470639. DOI: 10.1007/s00432-022-04019-9.


Does the Microbiota Composition Influence the Efficacy of Colorectal Cancer Immunotherapy?.

Lin Y, Kong D, Zhang Y Front Oncol. 2022; 12:852194.

PMID: 35463305 PMC: 9023803. DOI: 10.3389/fonc.2022.852194.


References
1.
Aleman J, Eusebi L, Ricciardiello L, Patidar K, Sanyal A, Holt P . Mechanisms of obesity-induced gastrointestinal neoplasia. Gastroenterology. 2013; 146(2):357-373. PMC: 3978703. DOI: 10.1053/j.gastro.2013.11.051. View

2.
Ogino S, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G . Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol. 2005; 19(1):59-68. DOI: 10.1038/modpathol.3800482. View

3.
Nishihara R, VanderWeele T, Shibuya K, Mittleman M, Wang M, Field A . Molecular pathological epidemiology gives clues to paradoxical findings. Eur J Epidemiol. 2015; 30(10):1129-35. PMC: 4639412. DOI: 10.1007/s10654-015-0088-4. View

4.
Song M, Nishihara R, Wang M, Chan A, Qian Z, Inamura K . Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut. 2015; 65(2):296-304. PMC: 4503524. DOI: 10.1136/gutjnl-2014-308852. View

5.
Ogino S, Nosho K, Kirkner G, Kawasaki T, Meyerhardt J, Loda M . CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2008; 58(1):90-6. PMC: 2679586. DOI: 10.1136/gut.2008.155473. View